ImageneBio (IMA) H.C. Wainwright 28th Annual Global Investment Conference summary

Company and lead asset overview

• Headquarters located in Del Mar, San Diego, with Olevaprubart (Oleva) as the lead program targeting OX40 for atopic dermatitis and alopecia areata.

• Olevaprubart is a next-generation, receptor-directed monoclonal antibody, engineered for high differentiation and efficacy.

Differentiation and clinical rationale

• Olevaprubart targets the OX40 receptor, is non-T cell depleting, and has a long half-life, enabling patient-friendly dosing intervals.

• The antibody silences ADCC function, preserving T cells and reducing adverse events seen with prior OX40-targeting drugs.

• Ongoing phase IIb adaptive study evaluates monthly and quarterly dosing, with potential for even wider intervals.

Safety and risk mitigation

• No cases of Kaposi sarcoma observed in trials; study design includes careful patient selection and monitoring for HHV-8.

• Investigator training and inclusion/exclusion criteria aim to minimize risk, with ongoing vigilance for safety signals.